

00 AUG 11 AM 9:58

VIA AIRBORNE EXPRESS

August 10, 2000

Secretary of the Senate
Office of the Public Records
232 Hart Senate Office Building
Washington, DC 20510

Clerk of the House of Representatives
Legislative Resource Center
B-106 Cannon House Office Building
Washington, DC 20515


RE: Form LD-2, Lobbying Report- AstraZeneca Pharmaceuticals LP

Dear Sir or Madam:

Enclosed please find two original Form LD-2 Lobbying Reports for AstraZeneca Pharmaceuticals LP (ID No. 34975000) for the first half of 2000.

If you have any questions or require more information, please telephone me directly at (302) 886-3690.

Very truly yours,



Luke W. Mette
Attorney

LWM/nmc
Enclosure

AstraZeneca A Business Unit of Zeneca Inc.
1800 Concord Pike PO Box 15437 Wilmington DE 19850-5437

Tel 302 886 3000
www.astrazeneca-us.com

AZ9161201

Clerk of the House of Representatives
Legislative Resource Center
B-106 Cannon Building
Washington, DC 20515

Secretary of the Senate
Office of Public Records
232 Hart Building
Washington, DC 20510

SECRETARY OF THE SENATE
00 AUG 11 AM 9:58

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required To Complete This Page

1. Registrant Name AstraZeneca Pharmaceuticals LP		ID No. 34975000
2. Address <input type="checkbox"/> Check if different than previously reported 1800 Concord Pike, P.O. Box 15437		
3. Principal Place of Business (if different from line 2) City: Wilmington State/Zip (or Country) DE 19850-5437		
4. Contact Name Luke W. Mette	Telephone (302) 886-3690	5. Senate ID #
7. Client Name <input checked="" type="checkbox"/> Self	6. House ID # ID No. 34975000	

TYPE OF REPORT 8. Year 2000 Midyear (January 1-June 30) ☒ OR Year End (July 1-December 31) ☐

9. Check if this filing amends a previously filed version of this report ☐


10. Check if this is a Termination Report ☐ ⇒ Termination Date _____

11. No Lobbying Activity ☐

INCOME OR EXPENSES - Complete Either Line 12 OR Line 13

12. Lobbying Firms INCOME relating to lobbying activities for this reporting period was: Less than \$10,000 <input type="checkbox"/> \$10,000 or more <input type="checkbox"/> ⇒ \$ _____ Income (nearest \$20,000) Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).	13. Organizations EXPENSES relating to lobbying activities for this reporting period were: Less than \$10,000 <input type="checkbox"/> \$10,000 or more <input checked="" type="checkbox"/> ⇒ \$ 320,000.00 Expenses (nearest \$20,000) 14. REPORTING METHOD. Check box to indicate expense accounting method. See instructions for description of options. <input checked="" type="checkbox"/> Method A. Reporting amounts using LDA definitions only <input type="checkbox"/> Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code <input type="checkbox"/> Method C. Reporting amounts under section 162(e) of the Internal Revenue Code
--	--

Signature



Printed Name and Title Luke W. Mette, Attorney

FD-278 (Rev. 5/01)

PAGE 1 of 5

Registrant Name AstraZeneca Pharmaceuticals LP Client Name Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code GOV (one per page)

16. Specific lobbying issues

National Toxicology Program - Issues Related to the Publication of The Ninth Report on Carcinogens

17. House(s) of Congress and Federal agencies contacted ☐ Check if None

U.S. House of Representatives
U.S. Senate
Department of Health & Human Services

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
James P. Schlicht - Executive Director Fed GOVT. AFFAIRS	The Honorable Donna Shalala	<input type="checkbox"/>
Stephen D. McMillan - Senior Mgr. Fed. Govt. Affairs		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above ☒ Check if None

Signature _____ Date _____

Printed Name and Title Luke W. Mette, Attorney

AstraZeneca Pharmaceuticals LP
Registrant Name _____ Client Name Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code HCR (one per page)

16. Specific lobbying issues

H.R. 4680 - Medicare Rx2000 Act
S. 2807 - Medicare 2000 Act
S. 2836 - Medicare Rx Drug Discount: Security Act of 2000
Calls, Letters & Visits In Support of A Private Sector, Premium Support Approach to a Medicare Drug Benefit

17. House(s) of Congress and Federal agencies contacted ☐ Check if None

U. S. House of Representatives
U.S. Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	Net
James P. Schlicht - Executive Director, Fed. Govt. Affairs		<input type="checkbox"/>
Stephen D. McMillan - Senior Mgr, Fed. Govt. Affairs		<input type="checkbox"/>
Dyan McGrath - Senior Mgr, Fed. Govt. Affairs		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above ☒ Check if None

Signature _____ Date _____

Printed Name and Title Luke W. Mette, Attorney

Page 3 of 5

Registrant Name AstraZeneca Pharmaceuticals LP Client Name Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code EUD (one per page)

16. Specific lobbying issues

H.R. 4461 / S. 2536 - Agriculture, FDA & Related Agencies Appropriations,
FY 2001 - Calls & Visits to Members Regarding:

- 1) FDA Appropriation Levels - Support
- 2) Foreign Importation Provisions (Coburn, Crowley & Jeffords) - Oppose

17. House(s) of Congress and Federal agencies contacted

☐ Check if None

U.S. House of Representatives
U.S. Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	Yes
James P. Schlicht - Executive Director, Fed. Govt. Affairs		<input type="checkbox"/>
Stephen D. McMillan - Senior Mgr. Fed. Govt. Affairs		<input type="checkbox"/>
Dyan McGrath - Senior Mgr., Fed. Govt. Affairs		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above

☒ Check if None

Signature

Date

Printed Name and Title Luke W. Matte, Attorney

Registrant Name AstraZeneca Pharmaceuticals LP Client Name Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code TRD (one per page)

16. Specific lobbying issues

H.R. 434 - Africa Trade & Development Act of 1999
1) Section 116 - Oppose


17. House(s) of Congress and Federal agencies contacted ☐ Check if None

U.S. House of Representatives
U.S. Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
James P. Schlicht - Executive Director, Federal Gov't. Affairs		<input type="checkbox"/>
Dyan McGrath - Senior Manager, Federal Gov't. Affairs		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above ☒ Check if None

Signature  Date 8/10/00
Printed Name and Title Luke W. Mette, Attorney

Page 5 of 5